GlassScriptPhysician profile
Samuel J Dail
NPI 1255710331
$3,241.83
in general payments reported to CMS, 2019-2025
32 companies · $208 in 2025
The $208 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $809 · 2020: $382 · 2021: $515 · 2022: $438 · 2023: $528 · 2024: $362 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,097.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,097.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $554.05 | 2019-2024 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $406.67 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $365.95 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $254.66 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $217.38 | 2019-2021 | |
| Abbvie INC. | $190.26 | 2022-2025 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $123.46 | 2019-2024 | Farxiga |
| Axsome Therapeutics, INC. | $112.32 | 2023-2025 | Auvelity |
| Pfizer INC. | $111.60 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.79 | 2021-2023 | Jardiance |
| Baxter Healthcare | $84.03 | 2023-2024 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Takeda Pharmaceuticals U.S.A., INC. | $81.37 | 2020-2025 | Trintellix |
| Novartis Pharmaceuticals Corporation | $78.38 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $61.82 | 2020-2021 | |
| Eisai INC. | $61.00 | 2020-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $46.63 | 2019-2020 | |
| Daiichi Sankyo INC. | $46.21 | 2021-2023 | Injectafer |
| Tolmar, INC. | $40.17 | 2025 | Jatenzo |
| Medtronic, INC. | $33.87 | 2023-2025 | Intellis Adaptivestim, Inceptiv |
| Esperion Therapeutics, INC. | $33.33 | 2020-2021 | |
| Abbott Laboratories | $29.87 | 2024 | Freestyle Libre 2 |
| Radius Health, INC. | $27.72 | 2019-2025 | Tymlos |
| Hikma Pharmaceuticals USA | $27.08 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $25.83 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $24.75 | 2020 | |
| Sanofi-Aventis U.S. LLC | $22.52 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $22.20 | 2023 | Givlaari |
| Almatica Pharma LLC | $16.19 | 2023 | Loreev Xr, Sertraline Hcl, Gralise |
| Mylan Specialty L.P. | $11.86 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $11.44 | 2020 | |
| Sumitomo Pharma America, INC. | $10.95 | 2023 | Gemtesa |
| Aroa Biosurgery Incorporated | $10.47 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Dail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.